IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

LANGLEY ET AL.

Appln. No.: 08/803,954

Group Art Unit: 1804

8/28/97

Filed: February 21, 1997

Examiner: Unknown

For: METALLOPROTEINASE INHIBITOR

August 18, 1997

INFORMATION DISCLOSURE STATEMENT

RECEIVED

AUG 2 1 1997

GROUP 1800

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In accordance with 37 CFR 1.56, 1.97, and 1.98, enclosed is Form PTO-1449, which lists each document made of reference in parent application 08/212,660. Applicants will provide copies of each cited document if requested by the Examiner.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR 1.97(f) to enable Applicants to comply fully.

Consideration of the foregoing and the enclosures plus the return of the enclosed Form PTO-1449 with the Examiner's initials in the left hand column per MPEP 609 are earnestly solicited.

Respectfully submitted,

BELL, BOYD & LLOYD

BELL, BOYD & LLOYD 1615 L Street, NW P.O. Box 65331 Washington, DC 20035-5331 Tel.: (202) 466-6300

Dante J. Picciano

Reg. No. 33,543

TRAI	NSMITTAL OF (U	Docket No. 0109063/020				
In Re	Application Of: I	AUG 2: 1997				
	Serial No.	Filing The 1991	Examiner	Group Art Unit		
). · (08/803,954	February 21, 1993	Unknown	1804		
Title:	METALLOPRO	TEINASE INHIBITOR				
Address to: Assistant Commissioner for Patents Washington, D.C. 20231						
		37 CF	R 1.97(b)			
1. 🛚	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.					
**	37 CFR 1.97(c)					
2. 🔲	The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:					
	1.	a Final Action under 37 CFR 1.11	3, or			
	2. a Notice of Allowance under 37 CFR 1.311,					
	whichever occurs first.					
	Also submitted herewith is:					
	□ a certification as specified in 37 CFR 1.97(e);					
	OR					
	the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).					

TRANSMITTAL OF (Ui	Docket No. 0109063/020			
In Re Application Of: L	ANGLEY et al.			
Serial No. Filing Date		Examiner	Group Art Unit	
08/803,954	February 21, 1997	Unknown	1804	
Title: METALLOPRO	TEINASE INHIBITOR			
Payment of Fee (Only complete If Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. Charge any additional fee required. Certificate of Transmission by Facsimile* Certificate of Transmission by Facsimile* I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patient and Trademark Office (Fax. No. 100 (Date) Signature Signature Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Correspondence Typed or Printed Name of Person Mailing Correspondence				
•				